The first late-stage test of an LSD-based medicine for generalized anxiety disorder has reported a positive result. Definium Therapeutics said its Phase 3 Voyage study met its primary endpoint, with a single dose producing a larger reduction in anxiety symptoms than placebo at 12 weeks.
The company reported in its topline announcement that the least-squares mean change in the Hamilton Anxiety Rating Scale at week 12 was a drop of 11.6 points among participants who received DT120, an orally disintegrating tablet formulation of lysergide, compared with a drop of 6.2 points in the placebo group. That is a placebo-adjusted difference of 5.4 points, which the company reported as statistically significant with a standardized effect size of 0.81.
Voyage randomized 214 adults (107 per group) at roughly 35 U.S. sites. Participants had a confirmed diagnosis of generalized anxiety disorder and a Hamilton score of at least 20 at screening and baseline. Mean baseline scores were 28.4 in the treatment group and 27.4 on placebo.
This is a topline announcement from a company, not a peer-reviewed publication, and that distinction should stay in view. Full data have not been published or independently reviewed.
What the Trial Measured and What It Found
Three features of the design matter before any number is interpreted. The treatment is a single dose rather than a daily medication, a fundamental departure from how anxiety is currently treated. The primary endpoint sits at 12 weeks, meaning the question is durability rather than immediate effect. And the drug is administered in a clinic under monitoring, not dispensed for home use.
Beyond the primary endpoint, the company reported that all key secondary endpoints were met. Improvement appeared early, with a placebo-adjusted 7.7-point difference on the anxiety scale at week one and a separation on the clinician-rated severity scale by day two. At week 12, 43 percent of treated participants had at least a 50 percent improvement in their anxiety score compared with 16 percent on placebo, and 14 percent reached remission compared with 4 percent.
On safety, the company said treatment-emergent adverse events were mild to moderate, transient, and mostly confined to the day of dosing, with no new safety signals and no suicidality signal or suicidal behavior. Participants were assessed hourly, starting 5 hours after dosing, against a structured end-of-session checklist, and the average time to meet these criteria was 6.4 hours, with 92 percent of participants meeting them by hour 8. That number is a practical detail rather than a footnote, because it describes how long a supervised session actually occupies a clinic.
The 12-week blinded period is followed by a 40-week open-label extension in which participants may receive up to four additional doses based on symptom severity. Those extension data are not final.
The Blinding Problem: The Second Trial Is Built to Address
A second Phase 3 study in the same indication, Panorama, has not yet been reported. The company expects topline data in September.
Panorama exists partly to address a specific methodological criticism of psychedelic trials. When a drug produces obvious perceptual effects, participants can often guess whether they received it, which can inflate results through expectation. Panorama randomizes participants 2:1:2 to a 100-microgram dose, a 50-microgram dose, and placebo, with the low dose intended to confound participants' ability to identify which condition they were assigned.
Definium has argued that its earlier Phase 2b work indicates the drug's clinical activity is not attributable to functional unblinding. That remains a contested question in the field rather than a settled one, and Voyage itself did not include a low-dose arm.
The Result That Came First
The reason expectations were elevated is that it was a different trial under different conditions. In June, Definium reported that its Phase 3 Emerge study in major depressive disorder met its primary endpoint. A single 100-microgram dose produced an 8.1-point placebo-adjusted improvement on the Montgomery-Asberg Depression Rating Scale at week six, with a 7.3-point placebo-adjusted improvement still present at week 12. The company reported no serious adverse events and no suicidality signal.
Emerge enrolled 149 participants across 20 sites, according to the study's design details. Chief executive Rob Barrow described the depression data as unprecedented, a characterization that is the company's own and that independent researchers have not yet had the full dataset to evaluate.
DT120 holds FDA breakthrough therapy designation for generalized anxiety disorder. Definium, which was known as MindMed until it rebranded in January, is also developing the compound for post-traumatic stress disorder.
The Distance Between a Trial Result and a Prescription
A positive readout leaves substantial ground between this week's news and anything a patient could receive.
Lysergide is a Schedule I controlled substance. Approval would require rescheduling before commercial distribution, a process involving the Drug Enforcement Administration, which operates on its own timeline. The company has not announced a submission date for a new drug application, and a second Phase 3 result in anxiety is still pending.
Delivery is the other constraint. A single-dose, clinic-administered psychedelic treatment requires monitored sessions of roughly six to eight hours, trained staff, and physical space. Health systems do not currently have that infrastructure at scale, and payer coverage for the administration itself would need to be established.
None of this argues against the science. It argues against reading a topline press release as an imminent treatment option. Generalized anxiety disorder affects an estimated 26 million U.S. adults and the last new FDA approval for the condition came in 2007, which is precisely why a positive result attracts this much attention and why careful reading matters.
Guidance for Patients Following This Story
Anyone living with generalized anxiety disorder should treat this coverage as news about drug development rather than as information about their own treatment.
Nobody should stop, start, or adjust a prescribed medication based on a trial announcement. Established treatments for generalized anxiety disorder, including cognitive behavioral therapy and several classes of medication, remain the standard of care and have not changed.
Obtaining LSD outside a clinical trial is illegal and unsafe. Street products carry unknown identity, purity, and dose, and the controlled clinic setting with hours of monitoring is a substantial part of what the trials are testing. Psychedelics also carry meaningful risk for people with personal or family histories of psychosis or bipolar disorder, which is why trials screen for those conditions.
The same gap between marketing and evidence shows up across this space, a pattern MedicalDaily documented in reporting on peptides labeled for research only that people are buying and injecting anyway.
People interested in participating in research can search registered trials at ClinicalTrials.gov and should discuss eligibility with their own clinician. MedicalDaily will report the Panorama result, the peer-reviewed publication of the Voyage data, and any regulatory filing the company announces.
If you are struggling with anxiety or your mental health, help is available. In the United States, the 988 Suicide and Crisis Lifeline can be reached by calling or texting 988.
Key Questions Answered
What did the trial find? Voyage met its primary endpoint. A single 100-microgram dose of DT120 produced a placebo-adjusted 5.4-point greater reduction in Hamilton Anxiety Rating Scale scores at week 12, with an effect size of 0.81.
How large was the study? It randomized 214 adults, 107 per group, across roughly 35 U.S. sites, all with a confirmed generalized anxiety disorder diagnosis and a Hamilton score of at least 20.
Is this peer-reviewed? No. These are topline results announced by the company. Full data have not been published or independently evaluated.
What about safety? The company reported adverse events that were mild to moderate, transient, and mostly on the dosing day, with no new safety signals and no suicidality signal.
What comes next? Topline results from Panorama, a second Phase 3 study in the same condition that includes a low-dose comparison arm, are expected in September.
Could this be prescribed soon? No. Lysergide is a Schedule I controlled substance requiring rescheduling; no new drug application date has been announced, and clinic-based administration infrastructure does not currently exist at scale.
What should patients do now? Continue current treatment and do not adjust any medication based on trial news. Obtaining LSD outside a trial is illegal and unsafe.
